Logo of jexpmedHomeThe Rockefeller University PressEditorsContactInstructions for AuthorsThis issue
J Exp Med. 1996 Nov 1; 184(5): 1781–1790.
PMCID: PMC2192859

Decreased tumor surveillance in perforin-deficient mice


Immune surveillance against tumors usually depends on T cell recognition of tumor antigens presented by major histocompatibility complex (MHC) molecules, whereas MHC class I- tumors may be controlled by natural killer (NK) cells. Perforin-dependent cytotoxicity is a major effector function of CD8+ MHC class I-restricted T cells and of NK cells. Here, we used perforin-deficient C57BL/6 (PKO) mice to study involvement of perforin and Fas ligand in tumor surveillance in vivo. We induced tumors in PKO and normal C57BL/6 mice by (a) injection of different syngeneic tumor cell lines of different tissue origin in naive and primed mice; (b) administration of the chemical carcinogens methylcholanthrene (MCA) or 12-O-tetradecanoylphorbol-13-acetate (TPA) plus 7,12-dimethylbenzanthracene (DMBA), or (c) by injection of acutely oncogenic Moloney sarcoma virus. The first set of models analyzes the defense against a tumor load given at once, whereas the last two sets give information on immune defense against tumors at the very moment of their generation. Most of the tumor cell lines tested were eliminated 10-100-fold better by C57BL/6 mice in an unprimed situation; after priming, the differences were more pronounced. Lymphoma cells transfected with Fas were controlled 10-fold better by PKO and C57BL/6 mice when compared to untransfected control cells, indicating some role for FasL in tumor control. MCA-induced tumors arose more rapidly and with a higher incidence in PKO mice compared to C57BL/6 or CD8- deficient mice. DMBA+TPA-induced skin papillomas arose with similar high incidence and comparable kinetics in both mouse strains. C57BL/6 and PKO mice have a similar incidence of Moloney murine sarcoma and leukemia virus-induced sarcomas, but tumors are larger and regression is retarded in PKO mice. Thus, perforin-dependent cytotoxicity is not only a crucial mechanism of both cytotoxic T lymphocyte- and NK- dependent resistance to injected tumor cell lines, but also operates during viral and chemical carcinogenesis in vivo. Experiments addressing the role of Fas-dependent cytotoxicity by studying resistance to tumor cell lines that were stably transfected with Fas neither provided evidence for a major role of Fas nor excluded a minor contribution of Fas in tumor surveillance.

Full Text

The Full Text of this article is available as a PDF (743K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281–355. [PubMed]
  • Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 1992;58:143–175. [PubMed]
  • Van Pel A, van der Bruggen P, Coulie PG, Brichard VG, Lethé B, van den Eynde B, Uyttenhove C, Renauld JC, Boon T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev. 1995 Jun;145:229–250. [PubMed]
  • Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992 Dec 24;71(7):1093–1102. [PubMed]
  • Li Y, McGowan P, Hellström I, Hellström KE, Chen L. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol. 1994 Jul 1;153(1):421–428. [PubMed]
  • Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11:191–212. [PubMed]
  • Schrier PI, Bernards R, Vaessen RT, Houweling A, van der Eb AJ. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature. 305(5937):771–775. [PubMed]
  • Bernards R, Schrier PI, Houweling A, Bos JL, van der Eb AJ, Zijlstra M, Melief CJ. Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature. 305(5937):776–779. [PubMed]
  • Smith ME, Marsh SG, Bodmer JG, Gelsthorpe K, Bodmer WF. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5557–5561. [PMC free article] [PubMed]
  • Uyttenhove C, Maryanski J, Boon T. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression. J Exp Med. 1983 Mar 1;157(3):1040–1052. [PMC free article] [PubMed]
  • Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986 Feb 20;319(6055):675–678. [PubMed]
  • van den Broek MF, Kägi D, Zinkernagel RM, Hengartner H. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur J Immunol. 1995 Dec;25(12):3514–3516. [PubMed]
  • Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994 May 5;369(6475):31–37. [PubMed]
  • Garner R, Helgason CD, Atkinson EA, Pinkoski MJ, Ostergaard HL, Sorensen O, Fu A, Lapchak PH, Rabinovitch A, McElhaney JE, et al. Characterization of a granule-independent lytic mechanism used by CTL hybridomas. J Immunol. 1994 Dec 15;153(12):5413–5421. [PubMed]
  • Walsh CM, Matloubian M, Liu CC, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD, Ahmed R, Clark WR. Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10854–10858. [PMC free article] [PubMed]
  • Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H, Saito T, Katayama T, Yagita H, Okumura K, et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity. 1994 Aug;1(5):357–364. [PubMed]
  • Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994 Jul 22;265(5171):528–530. [PubMed]
  • Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994 Aug 25;370(6491):650–652. [PubMed]
  • Kägi D, Ledermann B, Bürki K, Hengartner H, Zinkernagel RM. CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur J Immunol. 1994 Dec;24(12):3068–3072. [PubMed]
  • Kägi D, Odermatt B, Ohashi PS, Zinkernagel RM, Hengartner H. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J Exp Med. 1996 May 1;183(5):2143–2152. [PMC free article] [PubMed]
  • Kägi D, Seiler P, Pavlovic J, Ledermann B, Bürki K, Zinkernagel RM, Hengartner H. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol. 1995 Dec;25(12):3256–3262. [PubMed]
  • Schulz M, Schuurman HJ, Joergensen J, Steiner C, Meerloo T, Kägi D, Hengartner H, Zinkernagel RM, Schreier MH, Bürki K, et al. Acute rejection of vascular heart allografts by perforin-deficient mice. Eur J Immunol. 1995 Feb;25(2):474–480. [PubMed]
  • Walsh CM, Hayashi F, Saffran DC, Ju ST, Berke G, Clark WR. Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection. J Immunol. 1996 Feb 15;156(4):1436–1441. [PubMed]
  • Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 1996 Feb 1;183(2):657–661. [PMC free article] [PubMed]
  • Fung-Leung WP, Schilham MW, Rahemtulla A, Kündig TM, Vollenweider M, Potter J, van Ewijk W, Mak TW. CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell. 1991 May 3;65(3):443–449. [PubMed]
  • Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 1992 Mar 6;68(5):855–867. [PubMed]
  • Doherty PC, Biddison WE, Bennink JR, Knowles BB. Cytotoxic T-cell responses in mice infected with influenza and vaccinia viruses vary in magnitude with H-2 genotype. J Exp Med. 1978 Aug 1;148(2):534–543. [PMC free article] [PubMed]
  • Puddington L, Bevan MJ, Rose JK, Lefrançois L. N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells. J Virol. 1986 Nov;60(2):708–717. [PMC free article] [PubMed]
  • Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ, Kast WM. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol. 1995 Apr 1;154(7):3396–3405. [PubMed]
  • Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. [PubMed]
  • Sheehan KC, Ruddle NH, Schreiber RD. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J Immunol. 1989 Jun 1;142(11):3884–3893. [PubMed]
  • Mackett M, Yilma T, Rose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science. 1985 Jan 25;227(4685):433–435. [PubMed]
  • Ehl S, Hoffmann-Rohrer U, Nagata S, Hengartner H, Zinkernagel R. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J Immunol. 1996 Apr 1;156(7):2357–2360. [PubMed]
  • Stukart MJ, Vos A, Melitef CJ. Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H-2 requirements. Eur J Immunol. 1981 Mar;11(3):251–257. [PubMed]
  • Pircher H, Moskophidis D, Rohrer U, Bürki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature. 1990 Aug 16;346(6285):629–633. [PubMed]
  • Fischer WH, Beland PE, Lutz WK. DNA adducts, cell proliferation and papilloma latency time in mouse skin after repeated dermal application of DMBA and TPA. Carcinogenesis. 1993 Jul;14(7):1285–1288. [PubMed]
  • Kündig TM, Bachmann MF, Lefrancois L, Puddington L, Hengartner H, Zinkernagel RM. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J Immunol. 1993 May 15;150(10):4450–4456. [PubMed]
  • Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 1994 Mar 15;54(6):1580–1586. [PubMed]
  • PREHN RT, MAIN JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed]
  • Bubbers JE, Lilly F. Selective incorporation of H-2 antigenic determinants into Friend virus particles. Nature. 1977 Mar 31;266(5601):458–459. [PubMed]
  • Bubbers JE, Chen S, Lilly F. Nonrandom inclusion of H-2K and H-2D antigens in Friend virus particles from mice of various strains. J Exp Med. 1978 Feb 1;147(2):340–351. [PMC free article] [PubMed]
  • Levy JP, Leclerc JC. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology? Adv Cancer Res. 1977;24:1–66. [PubMed]
  • Stukart MJ, Vos A, Boes J, Melvold RW, Bailey DW, Melief CJ. A crucial role of the H-2 D locus in the regulation of both the D- and the K-associated cytotoxic T lymphocyte response against Moloney leukemia virus, demonstrated with two Db mutants. J Immunol. 1982 Mar;128(3):1360–1364. [PubMed]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...